## MHS Health Wisconsin Calendar Year 2022 HEDIS® Measure Ratings:

The Healthcare Effectiveness Data and Information Set (HEDIS<sup>®</sup>) is a tool that helps health plans measure the quality of care their members receive. MHS Health uses HEDIS<sup>®</sup> data to identify areas for improvement and monitor progress. The chart below shows our progress on HEDIS measures and areas that need improvement, based on our Calendar Year 2022 HEDIS<sup>®</sup> scores.

progress on HEDIS measures and areas that need improvement, based on ou		ear 2022 HEDIS		
	Calendar		CY2022 Goal	Calendar
Measure	Year	Percentile	NCQA Quality	Year
Ivicasure	2022	Ranking	Compass 75 <sup>th</sup>	2021
	Results		Percentile	Results
Goal Met or Exce	eeded			
Adherence to Antipsychotic Medications for Individuals with	74.04	<b>ze</b> th		70.42
Schizophrenia	71.61	75 <sup>th</sup>	66.59	70.43
Antidepressant Medication Management Continuation	54.40	75 <sup>th</sup>	47.70	55.98
Appropriate Testing for Pharyngitis	81.15	90 <sup>th</sup>	76.30	77.31
Appropriate Treatment for Upper Respiratory Infection	94.25	75 <sup>th</sup>	93.85	85.97
Asthma Medication Ratio	72.22	75 <sup>th</sup>	69.67	66.30
Avoidance of Antibiotic Treatment in Acute				
Bronchitis/Bronchiolitis	68.51	75 <sup>th</sup>	61.64	55.35
Cervical Cancer Screening	62.77	75 <sup>th</sup>	62.53	60.20
Comprehensive Diabetes Care: BP Control <140/90	72.02	75 <sup>th</sup>	67.40	65.45
Comprehensive Diabetes Care: HbA1c Control (<8.0%)	54.74	75 <sup>th</sup>	54.26	44.53
Controlling High Blood Pressure	65.69	75 <sup>th</sup>	65.10	63.84
Follow-Up After Emergency Department Visit for Alcohol or	05.05		05.10	05.04
Other Drug Abuse or Dependence: 7 days	24.07	90 <sup>th</sup>	17.22	16.01
	50.18	75 <sup>th</sup>	46.02	47.85
Follow-Up After Hospitalization for Mental Illness: 7 days	50.16	75	40.02	47.05
Pharmacotherapy Management of COPD Exacerbation: Bronchodilator	90.36	75 <sup>th</sup>	88.67	88.67
	00.0F	75 <sup>th</sup>	00.00	02.02
Prenatal Care	89.05	/5***	88.86	83.92
Statin Therapy for Patients with Cardiovascular Disease -	81.25	90 <sup>th</sup>	76.22	86.63
Statin Adherence		e eth		
Statin Therapy for Patients with Diabetes - Statin Adherence	77.97	90 <sup>th</sup>	71.87	82.01
On Track with Nationa			Γ	
Breast Cancer Screening	51.58	50 <sup>th</sup>	56.52	52.76
Use of Imaging Studies for Low Back Pain	74.55	50 <sup>th</sup>	78.30	80.39
Pharmacotherapy Management of COPD Exacerbation:	76.51	67 <sup>th</sup>	76.87	83.33
Corticosteroid	70.51	07	70.87	03.33
Postpartum Care	79.32	50 <sup>th</sup>	81.27	75.73
Statin Therapy for Patients with Diabetes - Received Statin	66.92	50 <sup>th</sup>	69.52	68.04
Therapy	00.92	50	09.32	00.04
Needs Improven	ment			
Annual Dental Visits	34.50	10 <sup>th</sup>	55.89	28.67
Childhood Immunization Status (Combo 10)	32.36	33 <sup>rd</sup>	42.09	30.66
Chlamydia Screening in Women	54.17	33 <sup>rd</sup>	62.65	53.61
Comprehensive Diabetes Care: Eye Exam	46.47	25 <sup>th</sup>	56.51	51.09
Diabetes Screening for People with Schizophrenia or Bipolar				
Disorder Who are Using Antipsychotic Medications	78.29	33 <sup>rd</sup>	82.26	70.66
Follow-Up After Emergency Department Visit for Mental				
Illness: 7 days	33.87	33 <sup>rd</sup>	50.39	46.64
Follow-Up for Children on ADHD Medication - Continuation				
and Maintenance Phase	46.00	25 <sup>th</sup>	57.53	53.66
Initiation and Engagement of Alcohol and Other Drug				
Dependence Treatment: Engagement	13.39	33 <sup>rd</sup>	17.93	14.46
Immunizations for Adolescents - Combination 2	32.35	33 <sup>rd</sup>	41.12	30.37
Metabolic Monitoring for Children and Adolescents on	52.55		41.12	30.37
	21.25	< 5 <sup>th</sup>	42.55	14.10
Antipsychotics: Blood Glucose and Cholesterol Testing	<b>F 7</b> C	10 <sup>th</sup>	2.09	Γ 41
Risk of Continued Opioid Use - 31 day (lower is better)	5.76	10	2.08	5.41
Statin Therapy for Patients with Cardiovascular Disease -	78.53	25 <sup>th</sup>	83.20	78.34
Received Statin Therapy				
Use of First-Line Psychosocial Care for Children and	61.54	33 <sup>rd</sup>	69.30	61.90
Adolescents on Antipsychotics				
Use of Opioids at High Dosage (lower rate is better)	25.78	< 5 <sup>th</sup>	2.04	23.36
		aard	0.74	2.33
Use of Opioids from Multiple Providers - Multiple	1.86	3310	11 74	
Prescribers and Multiple Pharmacies (lower rate is better)	1.86	33 <sup>rd</sup>	0.74	2.55
	1.86 73.24	25 <sup>th</sup>	84.43	80.05